Why Puma Biotechnology (PBYI) Stock Is SpikingToday?

NEW YORK (TheStreet) -- Puma Biotechnology (PBYI) shares are up 290% to $232 in trading on Wednesday after the company reported positive top-line results from the Phase 3 trial of its neratinib breast cancer treatment.

Analysts at Citigroup (C) are speculating that the company is now a takeover target after Puma reported that patients who received the drug treatment showed a 33% improvement in disease-free survival rates versus a placebo.

Puma's stock price has more than tripled since its $59.03 closing price on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PBYI Chart PBYIPBYI Chart PBYI data by YCharts
data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer: Schlumberger Predicted the Rise in Oil Prices

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on Zillow's New Business: Buying and Selling Homes

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Jim Cramer on the Markets: It's Natural to Have Some Profit Taking

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks

Video: As Trade Worries Subside, Expect a 'Relief Rally' in Stocks

Stocks Trade Mixed Amid Progress on U.S.-China Trade; Dow Turns Lower

Stocks Trade Mixed Amid Progress on U.S.-China Trade; Dow Turns Lower